Radhoe SP, Veenis JF, Linssen GCM, et al. - Diabetes mellitus was highly prevalent in this large real-world heart failure (HF) registry and guideline-recommended target doses were more often prescribed in patients with diabetes. Based on current evidence, most of the patients would satisfy the enrichment criteria of sodium–glucose cotransporter 2 trials in HF and the effect of this new drug class will be huge.

• This study included 7,488 patients with chronic HF with a left ventricular ejection fraction <50%, with average age 72.8 years (±11.7 years), and 64% were men.

• Of participants, 29% (n = 2174) had diabetes, and a worse renal function was seen in diabetics.

• Diabetics vs non-diabetics were less often prescribed renin–angiotensin system inhibitors (79% vs 82%), while there were no significant differences regarding other guideline-recommended HF drugs.

• Patients with diabetes were more often prescribed target doses of beta-blockers (23% vs 16%), renin–angiotensin system inhibitors (47% vs 43%), and mineralocorticoid receptor antagonists (57% vs 51%) than non-diabetics.